Raynaud's phenomenon
- 1 June 2001
- journal article
- review article
- Published by Elsevier BV in The Lancet
- Vol. 357 (9273), 2042-2048
- https://doi.org/10.1016/s0140-6736(00)05118-7
Abstract
No abstract availableKeywords
This publication has 65 references indexed in Scilit:
- Losartan therapy for Raynaud's phenomenon and scleroderma: Clinical and biochemical findings in a fifteen-week, randomized, parallel-group, controlled trialArthritis & Rheumatism, 1999
- Association between Cigarette and Alcohol Consumption and Raynaud’s PhenomenonJournal of Clinical Epidemiology, 1999
- Different factors influencing the expression of Raynaud's phenomenon in men and womenArthritis & Rheumatism, 1999
- An objective method to estimate the severity of Raynaud phenomenon: digital blood pressure response to coolingVascular Medicine, 1998
- Familial aggregation of primary Raynaud's diseaseArthritis & Rheumatism, 1996
- Calcitonin gene-related peptide, endothelin-1, the cutaneous microvasculature and Raynaud's phenomenonBritish Journal of Dermatology, 1996
- Long-term outcome of Raynaud's syndrome in a prospectively analyzed patient cohortJournal of Vascular Surgery, 1996
- SUSTAINED-RELEASE TRANSDERMAL GLYCERYL TRINITRATE PATCHES AS A TREATMENT FOR PRIMARY AND SECONDARY RAYNAUD'S PHENOMENONRheumatology, 1995
- Calcitonin gene-related peptide in treatment of severe peripheral vascular insufficiency in Raynaud's phenomenonThe Lancet, 1993
- Plasma free and intraplatelet serotonin in patients with Raynaud's phenomenonInternational Journal of Cardiology, 1988